Overview

Anlotinib Hydrochloride Combined With Liposomal Doxorubicin in the Treatment of Locally Advanced or Metastatic Soft Tissue Sarcoma

Status:
Unknown status

Trial end date:
2021-05-01

Target enrollment:

Participant gender:

Summary

The investigators explored the activity of anlotinib combined with Liposomal Doxorubicin in patients with Locally Advanced or Metastatic Soft Tissue Sarcoma

Phase:

Phase 2

Details

Lead Sponsor:

Peking University People's Hospital

Collaborators:

Beijing Cancer Hospital
First Hospital of Jilin University
Hunan Cancer Hospital
Liaoning Tumor Hospital & Institute
Peking University Shougang Hospital
Ruijin Hospital
The First Hospital of Jilin University
Tianjin Medical University Cancer Institute and Hospital

Treatments:

Doxorubicin
Liposomal doxorubicin